NCT04232605 is a NA clinical trial of GLP-1 peptide in Headache, Migraine, sponsored by Danish Headache Center.

Who is sponsoring NCT04232605?

NCT04232605 is sponsored by Danish Headache Center.

What drugs are being tested in NCT04232605?

Interventions in NCT04232605: GLP-1 peptide, Placebo.

What condition does NCT04232605 study?

NCT04232605 studies Headache, Migraine.

Is NCT04232605 still recruiting?

NCT04232605 is currently status unknown. Last updated 18 January 2020.

Last reviewed 2020-01-18 · How we verify

NCT04232605

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Investigation of Vasodilation and Intensity of Headache Triggered by Glucagon Like Peptide-1 in Humans

Status unknown NA Last updated 18 January 2020

What this trial tests

NA trial testing GLP-1 peptide in Headache, Migraine in 43 participants. Status unknown.

Timeline

9 January 2020

Primary endpoint
31 December 2021

1 January 2022

Quick facts

Lead sponsor	Danish Headache Center
Phase	NA
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	randomized
Design	crossover
Masking	triple
Primary purpose	other
Enrollment	43
Start date	9 January 2020
Primary completion	31 December 2021
Estimated completion	1 January 2022
Sites	1 location across Denmark

Drugs / interventions tested

GLP-1 peptide
Placebo

Conditions studied

Headache, Migraine — all drugs for Headache, Migraine →

Sponsor

Danish Headache Center — full company profile →

Who can join

Adults 18 to 60, any sex, with Headache, Migraine. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Studying glucagon-like peptide-1 (GLP-1) induced vasodilatory effects on extra - and intracerebral arteries and headache in healthy volunteers and migraine patients without aura.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Headache, Migraine

Currently open trials in the same condition.

NCT06584409 — Migraines Accepted Laser Acupuncture Compared in Blood Test of MMP2 and CGRP · NA · recruiting
NCT05889624 — Responding With Evidence and Access for Childhood Headaches · NA · recruiting
NCT05232942 — Monoclonal Antibody Duration of REsponse in MIgraine After Treatment Interruption · recruiting
NCT04715685 — Mind Body Balance for Pediatric Migraine · NA · recruiting

Other Danish Headache Center trials

Trials by the same sponsor.

NCT07451769 — Selective Activation of the Adrenomedullin Receptors in Migraine · NA · not yet recruiting
NCT07342296 — Induction of Migraine Attacks With Aura Using Pituitary Adenylate Cyclase Activating Polypeptide-38 · NA · not yet recruiting
NCT07059546 — Hypersensitivity to Adrenomedullin in Post-Traumatic Headache · NA · recruiting
NCT07021859 — Induction of Migraine Attacks With Aura Using Calcitonin Gene-Related Peptide · NA · recruiting
NCT06959004 — Substance P-Induced Migraine Attacks Without Aura · NA · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04232605 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Danish Headache Center
Last refreshed: 18 January 2020

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04232605.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing